Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma (Q81565196)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

Yun Gong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Daniel J Booser

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Nour Sneige

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

1763-1769

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

9 January 2020

fluorescence in situ hybridization

1 reference

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

inferred from title

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

First-line Herceptin monotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.20987

1 reference

7 January 2021

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

HER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile Changing

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

The Measurement of Observer Agreement for Categorical Data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20987

7 January 2021

Identifiers

DOI

10.1002/CNCR.20987

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15786420%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference